Clinical trials have investigated the weight loss effect of glucagon‐like peptide‐1 receptor
agonists (GLP‐1 RA) in adults with obesity without diabetes mellitus, but results for weight …

We are facing a global epidemic of obesity and type 2 diabetes. Weight loss, in the context of
obesity and type 2 diabetes, may improve glycaemic control and weight‐related …

Objective: We investigated the effects of liraglutide on gastric emptying, glycemic
parameters, appetite and energy metabolism in obese non-diabetic individuals. Design …

Obesity is a global epidemic that contributes to a number of health complications including
cardiovascular disease, type 2 diabetes, cancer and neuropsychiatric disorders …

The obesity pandemic is accompanied by increased risk of developing metabolic syndrome
(MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic …

摘要背景: 胰高血糖素样肽‐1 (glucagon‐like peptide 1, GLP‐1) 受体激动剂对维持糖尿病患者
的体重有益. 我们通过分析以往的随机对照试验来了解该类药物在非糖尿病的肥胖/超重人群中 …

Diabetes is a growing global health concern, as is obesity. Diabetes and obesity are
intrinsically linked: obesity increases the risk of diabetes and also contributes to disease …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are new drugs for the
treatment of obesity. Objective To assess the weight-loss effects of GLP-1RAs in the …

Importance Medical treatment options for pediatric obesity remain limited. Glucagon-like
peptide-1 (GLP-1) receptor agonists induce weight loss by suppressing appetite and …

The hormone glucagon‐like peptide‐1 (GLP‐1) is released from the gut in response to food
intake. It acts as a satiety signal, leading to reduced food intake, and also as a regulator of …